SCHEMBL30456529

SCHEMBL30456529

Cc1ncccc1-c1ccc(C(=O)NC(C)(C)c2csc(NS(=O)(=O)C3CC3)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CTPS1 P17812 19/20 0.51
CTPS2 Q9NRF8 4/20 0.51
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24088713 1.00 CTPS1 (0.51) CTPS1CTPS2MKNK1MKNK2
SCHEMBL22490802 0.85 CTPS1 (0.70) CTPS1CTPS2
SCHEMBL21044431 0.82 CTPS1 (0.74) CTPS1CTPS2
SCHEMBL22490838 0.82 CTPS1 (0.56) CTPS1CTPS2
SCHEMBL22490818 0.81 CTPS1 (0.48) CTPS1CTPS2
SCHEMBL30455611 0.81 CTPS1 (0.48) CTPS1CTPS2
SCHEMBL22490771 0.81 CTPS1 (0.53) CTPS1CTPS2
SCHEMBL22490816 0.81 CTPS1 (0.60) CTPS1CTPS2
SCHEMBL22490786 0.80 CTPS1 (0.54) CTPS1CTPS2
SCHEMBL22490775 0.79 CTPS1 (0.54) CTPS1CTPS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717465-B1 COMPOUNDS STEP PHARMA S A S (FR) 2026-01-21 EP disclosed
US-12319680-B2 Compounds STEP PHARMA S.A.S. (FR) 2025-06-03 US disclosed
US-20230183229-A1 Compounds SYGNATURE DISCOVERY LIMITED (GB) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183229-A1 Compounds UGT1A1, CYP1A1, CYP1B1 CTPS1 2556/4885CTPS2 2833/4885MKNK1 2780/4885
US-12319680-B2 Compounds UGT1A1, CYP1A1, CYP1B1 CTPS1 2556/4885CTPS2 2833/4885MKNK1 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.